lemborexant

Details

Key Milestones2
Call for patient/clinician input open28-Feb-25
Call for patient/clinician input closed29-Apr-25
Submission received10-Apr-25
Submission accepted28-Apr-25
Review initiated29-Apr-25
Draft CADTH review report(s) provided to sponsor for comment14-Jul-25
Deadline for sponsors comments23-Jul-25
CDA-AMC review report(s) and responses to comments provided to sponsor15-Aug-25
Expert committee meeting (initial)27-Aug-25
Draft recommendation issued to sponsorSeptember 09, 2025
To
September 11, 2025
Draft recommendation posted for stakeholder feedback18-Sep-25
End of feedback period03-Oct-25

risankizumab

Details

Key Milestones2
Call for patient/clinician input open14-Feb-25
Call for patient/clinician input closed11-Apr-25
Submission received31-Mar-25
Submission accepted14-Apr-25
Review initiated15-Apr-25
Draft CADTH review report(s) provided to sponsor for comment03-Jul-25
Deadline for sponsors comments14-Jul-25
CDA-AMC review report(s) and responses to comments provided to sponsor15-Aug-25
Expert committee meeting (initial)27-Aug-25
Draft recommendation issued to sponsorSeptember 09, 2025
To
September 11, 2025
Draft recommendation posted for stakeholder feedback19-Sep-25
End of feedback period06-Oct-25